Treatment outcomes of mantle cell lymphoma in real-world practice: analysis of forty-one patients

[1] Swerdlow SH, Campo E, Seto M, Muller-Hermelink HK., Mantle cell lymphoma, WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, pp. 285-290, (2017)

[2] Dreyling M, Klapper W, Rule S., Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic chal-lenge!, Blood, 132, pp. 2722-2729, (2018)

[3] Aukema SM, Hoster E, Rosenwald A, Et al., Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network, Blood, 131, pp. 417-420, (2018)

[4] Hoster E, Dreyling M, Klapper W, Et al., A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma, Blood, 111, pp. 558-565, (2008)

[5] Eskelund CW, Dimopoulos K, Kolstad A, Et al., Detailed long-term follow-up of patients who relapsed after the Nordic mantle cell lymphoma trials: MCL2 and MCL3, Hemasphere, 5, (2020)

[6] Harmanen M, Hujo M, Sund R, Et al., Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective bina-tional analysis between 2000 and 2020, Br J Haematol, 201, pp. 64-74, (2023)

[7] Ogura M, Yamamoto K, Morishima Y, Et al., R‐High‐CHOP/ CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY, Cancer Sci, 109, pp. 2830-2840, (2018)

[8] Lenz G, Dreyling M, Hoster E, Et al., Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a pro-spective randomized trial of the German Low Grade Lymphoma Study Group (GLSG), J Clin Oncol, 23, pp. 1984-1992, (2005)

[9] Rummel MJ, Niederle N, Maschmeyer G, Et al., Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial, Lancet, 381, pp. 1203-1210, (2013)

[10] Robak T, Jin J, Pylypenko H, Et al., Frontline bortezomib, ritux-imab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineli-gible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study, Lancet Oncol, 19, pp. 1449-1458, (2018)

[1] Swerdlow SH, Campo E, Seto M, Muller-Hermelink HK., Mantle cell lymphoma, WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, pp. 285-290, (2017)

[2] Dreyling M, Klapper W, Rule S., Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic chal-lenge!, Blood, 132, pp. 2722-2729, (2018)

[3] Aukema SM, Hoster E, Rosenwald A, Et al., Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network, Blood, 131, pp. 417-420, (2018)

[4] Hoster E, Dreyling M, Klapper W, Et al., A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma, Blood, 111, pp. 558-565, (2008)

[5] Eskelund CW, Dimopoulos K, Kolstad A, Et al., Detailed long-term follow-up of patients who relapsed after the Nordic mantle cell lymphoma trials: MCL2 and MCL3, Hemasphere, 5, (2020)

[6] Harmanen M, Hujo M, Sund R, Et al., Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective bina-tional analysis between 2000 and 2020, Br J Haematol, 201, pp. 64-74, (2023)

[7] Ogura M, Yamamoto K, Morishima Y, Et al., R‐High‐CHOP/ CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY, Cancer Sci, 109, pp. 2830-2840, (2018)

[8] Lenz G, Dreyling M, Hoster E, Et al., Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a pro-spective randomized trial of the German Low Grade Lymphoma Study Group (GLSG), J Clin Oncol, 23, pp. 1984-1992, (2005)

[9] Rummel MJ, Niederle N, Maschmeyer G, Et al., Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial, Lancet, 381, pp. 1203-1210, (2013)

[10] Robak T, Jin J, Pylypenko H, Et al., Frontline bortezomib, ritux-imab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineli-gible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study, Lancet Oncol, 19, pp. 1449-1458, (2018)